All In Biotech

Drug Trial Radar · NCT01347866

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual Pi3k/Mtor Inhibitors Pf-04691502 And Pf-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Oct 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

105

Actual

Start

Oct 2011

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan. The study will assess safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer. Once the maximum tolerated doses are identified, further assessment of these combinations will be done in patients with previously treated metastatic colorectal or pancreatic cancer for the PF-05212384 plus irinotecan arm and in patients with ovarian cancer or KRAS mutated non small cell lung cancer for the combination of PF-05212384 plus PD-0325901.

Conditions

  • Advanced Cancer

Interventions

  • PF-05212384Drug

    PF-05212384 intravenous infusion weekly starting at 110 mg.

  • PD-0325901Drug

    PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off

  • PF-05212384Drug

    PF-05212384 intravenous infusion weekly starting at 95 mg.

  • irinotecanDrug

    Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle (28 Days)Time frame: Baseline up to 28 days

Locations

18 sites in 4 countries. Site status is shown where the registry gives one.

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • UCLA Medical Center

    Los Angeles, California

  • UCLA Oncology Center

    Los Angeles, California

  • Santa Monica - UCLA Medical Center and Orthopaedic Hospital

    Santa Monica, California

  • UCLA Santa Monica Hematology Oncology

    Santa Monica, California

  • Anschutz Cancer Pavilion

    Aurora, Colorado

  • University of Colorado Denver (CTRC)

    Aurora, Colorado

  • University of Colorado Hospital Anschutz Inpatient Pavilion

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • Medical University of South Carolina, Hollings Cancer Center

    Charleston, South Carolina

  • Medical University of South Carolina

    Charleston, South Carolina

  • MUSC, Investigational Drug Services

    Charleston, South Carolina

  • MUSC Health East Cooper

    Mt. Pleasant, South Carolina

  • MUSC Specialty Care-North

    North Charleston, South Carolina

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Ospedale San Raffaele

    Milan, Italy

  • Hospital General Vall d'Hebron

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.